scholarly journals A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses in vivo

2014 ◽  
Vol 5 (4) ◽  
pp. 1437-1441 ◽  
Author(s):  
S. Deng ◽  
L. Bai ◽  
R. Reboulet ◽  
R. Matthew ◽  
D. A. Engler ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Antibody Responses ◽  
Natural Killer T Cell ◽  
Cell Antigen ◽  
Killer T Cell ◽  
Natural Killer T

Vaccination of mice with liposomes containing an oligosaccharide and a natural killer T cell agonist results in generation of high titers of antibodies (IgM and IgG) for the oligosaccharide.

Galacto-Configured Aminocyclitol Phytoceramides Are Potent in Vivo Invariant Natural Killer T Cell Stimulators

2011 ◽  
Vol 133 (31) ◽  
pp. 12079-12084 ◽  
Author(s):  
Youssef Harrak ◽  
Carolina M. Barra ◽  
Antonio Delgado ◽  
A. Raúl Castaño ◽  
Amadeu Llebaria
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Natural Killer T Cell ◽  
Invariant Natural Killer ◽  
Killer T Cell ◽  
Natural Killer T

scholarly journals Human and Mouse Type I Natural Killer T Cell Antigen Receptors Exhibit Different Fine Specificities for CD1d-Antigen Complex

2012 ◽  
Vol 287 (46) ◽  
pp. 39139-39148 ◽  
Author(s):  
Kwok S. Wun ◽  
Fiona Ross ◽  
Onisha Patel ◽  
Gurdyal S. Besra ◽  
Steven A. Porcelli ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Type I ◽  
Antigen Receptors ◽  
Natural Killer T Cell ◽  
Cell Antigen ◽  
Antigen Complex ◽  
Human And Mouse ◽  
Killer T Cell ◽  
Natural Killer T

scholarly journals CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mei Mei ◽  
Yingjun Wang ◽  
Wenting Song ◽  
Zhaoming Li ◽  
Qilong Wang ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Natural Killer T Cell ◽  
Potential Biomarker ◽  
Killer T Cell ◽  
Natural Killer T

Abstract Background Natural killer/T-cell lymphoma (NKTCL) is a rare and aggressive subtype of Non-Hodgkin’s Lymphoma. CircRNA has shown great potential to become a biomarker in plasma. In this study, we aimed to determine circRNA for its diagnostic and prognostic value and biological function in NKTCL. Method The circRNA microarray of plasma from NKTCL patients and healthy donors were conducted. The relative expressions of target circRNA were verified by qRT-PCR. We conducted function experiments in vitro and in vivo. Bioinformatics predicted the target miRNA of the target circRNA and the binding site was detected by the dual luciferase report assay. Downstream target protein was predicted and detected by western blot in vitro and immunohistochemistry in vivo. Result By analyzing the plasma circRNA microarrays in NKTCL, 6137 circRNAs were up-regulated and 6190 circRNAs were down-regulated. The relative expressions of circADARB1 were significantly higher in NKTCL patients. The knockdown of circADARB1 inhibited proliferation of NKTCL cells in vitro and in vivo. CircADARB1 could bind to miR-214-3p in the downstream and regulate the expression of p-Stat3. In nude mice tumor tissue, p-Stat3 was under-expressed in the circADARB1 knockdown group. Conclusion CircADARB1 was highly expressed in NKTCL plasma and circADARB1 was a potential biomarker to assist diagnosis and predict the response in NKTCL. CircADARB1 bound up to miR-214-3p and regulated p-Stat3.

The CD1d natural killer T-cell antigen presentation pathway is highly conserved between humans and rhesus macaques

2003 ◽  
Vol 54 (11) ◽  
pp. 776-781 ◽  
Author(s):  
Koichi Kashiwase ◽  
Akiko Kikuchi ◽  
Yoshitaka Ando ◽  
Andrew Nicol ◽  
Steven A. Porcelli ◽  
...  
Keyword(s):  
T Cell ◽  
Antigen Presentation ◽  
Natural Killer ◽  
Rhesus Macaques ◽  
Natural Killer T Cell ◽  
Cell Antigen ◽  
Antigen Presentation Pathway ◽  
Presentation Pathway ◽  
Killer T Cell ◽  
Natural Killer T

Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor

2012 ◽  
Vol 13 (9) ◽  
pp. 857-863 ◽  
Author(s):  
Onisha Patel ◽  
Daniel G Pellicci ◽  
Stephanie Gras ◽  
Maria L Sandoval-Romero ◽  
Adam P Uldrich ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Antigen Receptor ◽  
Type Ii ◽  
T Cell Antigen Receptor ◽  
Cell Antigen Receptor ◽  
Natural Killer T Cell ◽  
Cell Antigen ◽  
Killer T Cell ◽  
Natural Killer T

scholarly journals Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide

2003 ◽  
Vol 198 (11) ◽  
pp. 1631-1641 ◽  
Author(s):  
John Schmieg ◽  
Guangli Yang ◽  
Richard W. Franck ◽  
Moriya Tsuji
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Therapeutic Option ◽  
Interferon Γ ◽  
Th2 Cytokines ◽  
Natural Killer T Cell ◽  
Melanoma Metastases ◽  
Killer T Cell ◽  
Natural Killer T

α-Galactosylceramide (α-GalCer) is a glycolipid that stimulates natural killer T cells to produce both T helper (Th) 1 and Th2 cytokines. This property enables α-GalCer to ameliorate a wide variety of infectious, neoplastic, and autoimmune diseases; however, its effectiveness against any one disease is limited by the opposing activities of the induced Th1 and Th2 cytokines. Here, we report that a synthetic C-glycoside analogue of α-GalCer, α-C-galactosylceramide (α-C-GalCer), acts as natural killer T cell ligand in vivo, and stimulates an enhanced Th1-type response in mice. In two disease models requiring Th1-type responses for control, namely malaria and melanoma metastases, α-C-GalCer exhibited a 1,000-fold more potent antimalaria activity and a 100-fold more potent antimetastatic activity than α-GalCer. Moreover, α-C-GalCer consistently stimulated prolonged production of the Th1 cytokines interferon-γ and interleukin (IL)-12, and decreased production of the Th2 cytokine IL-4 compared with α-GalCer. Finally, α-C-GalCer's enhanced therapeutic activity required the presence of IL-12, which was needed to stimulate natural killer cells for optimal interferon-γ production, but did not affect IL-4. Overall, our results suggest that α-C-GalCer may one day be an excellent therapeutic option for diseases resolved by Th1-type responses.

Sign in / Sign up

Export Citation Format

Share Document